Patents by Inventor Himanshu Brahmbhatt

Himanshu Brahmbhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9878043
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: January 30, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid
  • Patent number: 9867785
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: January 16, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 9844598
    Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: December 19, 2017
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20170326235
    Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Applicant: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
  • Publication number: 20170258734
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 14, 2017
    Applicant: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 9731011
    Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: August 15, 2017
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 9730897
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: August 15, 2017
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20160113883
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Application
    Filed: December 29, 2015
    Publication date: April 28, 2016
    Applicant: EnGenelC Molecular Delivery Pty. Ltd.
    Inventors: HIMANSHU BRAHMBHATT, JENNIFER MACDIARMIID
  • Publication number: 20160095941
    Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
    Type: Application
    Filed: October 2, 2015
    Publication date: April 7, 2016
    Applicant: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20160051687
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: June 19, 2015
    Publication date: February 25, 2016
    Applicant: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 9242007
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: January 26, 2016
    Assignee: EnGeneIC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20150343092
    Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 3, 2015
    Applicant: EnGenelC Molecular Delivery Pty Ltd.
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
  • Patent number: 9169495
    Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: October 27, 2015
    Assignee: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid
  • Patent number: 9066982
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amount of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 30, 2015
    Assignee: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Publication number: 20150098897
    Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicant: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MACDIARMID
  • Patent number: 8956864
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 17, 2015
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid, Toby Hulf
  • Publication number: 20140315976
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Application
    Filed: January 10, 2014
    Publication date: October 23, 2014
    Applicant: EnGeneIC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20140221459
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: March 12, 2014
    Publication date: August 7, 2014
    Applicant: EnGeneIC Molecular Delivery Pty Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid, Toby Hulf
  • Publication number: 20140220116
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: EnGeneIC Gene Therapy Pty Limited
    Inventors: Himanshu Brahmbhatt, Jennifer MACDIARMID
  • Patent number: 8772013
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: July 8, 2014
    Assignee: Engeneic Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid